Myelodysplastic syndrome mortality profile from 2014 to 2018

  • Camila de Assunção Martins Pontifical Catholic University of Goiás
  • Camila Puton Pontifical Catholic University of Goiás
  • Liliane Emilly dos Santos Sousa Paulista University
  • Antonio Márcio Teodoro Cordeiro Silva Pontifical Catholic University of Goiás
Keywords: Myelodysplastic Syndrome; Leukemia; Neoplastic; Anemia.


INTRODUCTION: Myelodysplastic syndrome is characterized by a group of disorders resulting from bone marrow cell damage. At first, these cells interfere with the production of normal blood cells and can later become neoplastic, turning into a type of leukemia. The symptoms are due to the lack of one or more blood cell types and the most frequent are: anemia, leukopenia and thrombocytopenia. In addition, weight loss, fever and loss of appetite may appear. The diagnosis is made based on the patient's clinical history, physical examination and laboratory tests. AIM: To evaluate the myelodysplastic syndrome mortality profile, in the Brazilian population, by gender and age group, from 2014 to 2018. METHODS: This is a quantitative descriptive epidemiological study of the number of deaths due to myelodysplastic syndrome. Data were extracted from the Department of Informatics of the Unified Health System, through the Mortality System, and epidemiological data were identified between the years 2014 and 2018. RESULTS: From 2014 to 2018, 4,557 cases of deaths due to myelodysplastic syndrome were recorded. Considering the occurrence of deaths, by age group, it was observed that the most affected ages were 80 years or more, with 41.2% (n=1,877) of deaths, and from this number, it was found that the highest prevalence of mortality occurred in females (n=959). Such mortality was also increased in the 70-79 age group, with 28.3% of total deaths. It can also be observed that the lowest mortality rate is between the ages of 10 and 14 years (n=14). CONCLUSION: Myelodysplastic syndrome mortality is an important indicator of the population's living conditions and the quality of health care for the elderly, as this is the age group most vulnerable to mortality due to this disease. Therefore, it is necessary to evaluate the evolution of the number of deaths and adopt measures to control, prevent, and reduce their occurrence, identifying the causes and the age group with the highest risk of development and death due to myelodysplastic syndrome.

How to Cite
Martins, C., Puton, C., Sousa, L. E., & Silva, A. M. (2021). Myelodysplastic syndrome mortality profile from 2014 to 2018. Acta Scientiae Anatomica, 1(Suppl 2), 111-112. Retrieved from